ArrowMark Colorado Holdings LLC Has $8.85 Million Holdings in NewAmsterdam Pharma Company N.V. $NAMS

ArrowMark Colorado Holdings LLC reduced its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 13.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 310,999 shares of the company’s stock after selling 47,615 shares during the period. ArrowMark Colorado Holdings LLC owned approximately 0.27% of NewAmsterdam Pharma worth $8,845,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Duquesne Family Office LLC boosted its stake in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after buying an additional 1,091,525 shares during the period. ADAR1 Capital Management LLC boosted its stake in NewAmsterdam Pharma by 1.8% in the third quarter. ADAR1 Capital Management LLC now owns 114,359 shares of the company’s stock valued at $3,252,000 after buying an additional 2,000 shares in the last quarter. Squarepoint Ops LLC boosted its stake in shares of NewAmsterdam Pharma by 46.8% in the 3rd quarter. Squarepoint Ops LLC now owns 20,959 shares of the company’s stock valued at $596,000 after purchasing an additional 6,680 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after buying an additional 697,129 shares during the last quarter. Finally, Kennedy Capital Management LLC grew its position in NewAmsterdam Pharma by 972.9% during the 3rd quarter. Kennedy Capital Management LLC now owns 146,715 shares of the company’s stock worth $4,173,000 after acquiring an additional 133,040 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson sold 443,707 shares of NewAmsterdam Pharma stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the transaction, the chief executive officer owned 174,144 shares of the company’s stock, valued at $5,790,288. The trade was a 71.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the completion of the transaction, the insider owned 69,302 shares of the company’s stock, valued at $2,099,157.58. This trade represents a 59.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 1,466,933 shares of company stock worth $48,448,017. 20.84% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Trading Down 4.0%

NASDAQ:NAMS opened at $28.62 on Monday. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The firm’s 50 day moving average is $33.10 and its 200 day moving average is $33.47. The stock has a market capitalization of $3.29 billion, a PE ratio of -16.54 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. Research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus boosted their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Guggenheim increased their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Needham & Company LLC increased their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Finally, Wall Street Zen downgraded shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.10.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.